The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Novel advances in mesothelioma
Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, provides an overview of current developments in the mesothelioma treatment landscape. Prof. Baas highlights the potential of chemotherapy and immunotherapy combinations, especially with the approval of nivolumab, atezolizumab, and pembrolizumab. Numerous therapies such as pembrolizumab and lenvatinib are additionally being investigated as second-line treatments, especially in patients pre-treated with immunotherapy. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Baas reports consultancy fees from BMS including research funding; all finances are for the hospital.
